Life SciencesPharmaceuticalsTherapeutic AreaOrthopedics

Orthopedic Biomaterials Market Report Suite - Japan - 2020 - 2026 - MedSuite

Lowest Prices Guaranteed Length Publisher Published Date SKU
from $7,995 187 Pages iData Research, Inc. February, 2020 IDR16219496
Lowest Prices Guaranteed
Price from $7,995
Length 187 Pages
Publisher iData Research, Inc.
Published Date February, 2020
SKU IDR16219496

Orthopedic Biomaterials Market Report Suite - Japan - 2020 - 2026 - MedSuite

Throughout this medical market research, iData Research analyzed 16 orthobiologics companies in Japan and utilized their comprehensive methodology to understand the Market Sizes, Unit Sales, ASPs, Company Market Shares, and to create accurate forecasts.

While this MedSuitereport contains all of the Japanese Orthopedic Biomaterials market analysis, each of the market segments is also available as stand-alone MedCorereports. Additionally, this research includes an orthobiologics procedure volume analysis which can also be purchased as a separate report, MedPro.

Markets Covered

  • Procedure Volumes for the Japanese Orthopedic Biomaterials Devices – MedPro
  • Orthopedic Bone Graft Substitute Market - MedCore
  • Hyaluronic Acid Viscosupplementation Market - MedCore
Japanese Orthopedic Biomaterials Market Insights

A lack of product differentiation across similar injection cycle products has led to commoditization, which has stifled innovation and the further development of new products. The prices of HA viscosupplementation products in Japan have drastically decreased since their introduction and are among the lowest in the world.

In August 2018, Medtronic received PMDA approval for its Grafton® DBM allograft product, which is the first DBM allograft to be approved in Japan. Grafton® was commercially launched in February 2019. Growth of this product will be primarily driven by spine procedures and other orthopedic procedures that it is indicated for.

Overall, the Japanese orthopedic biomaterials market was valued at $426.9 million in 2019. This is expected to fluctuate over the forecast period with a -0.4% CAGR.


The full report suite on the Japan market for orthopedic biomaterials includes bone graft substitutes, which are represented by synthetics and DBM allografts. DBM allografts are discussed qualitatively. This report also includes hyaluronic acid (HA) viscosupplementation.


EXECUTIVE SUMMARY
JAPANESE ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW
COMPETITIVE ANALYSIS
MARKET TRENDS
MARKET DEVELOPMENTS
PROCEDURE NUMBERS
MARKETS INCLUDED
VERSION HISTORY
RESEARCH METHODOLOGY
Step 1: Project Initiation & Team Selection
Step 2: Prepare Data Systems and Perform Secondary Research
Step 3: Preparation for Interviews & Questionnaire Design
Step 4: Performing Primary Research
Step 5: Research Analysis: Establishing Baseline Estimates
Step 6: Market Forecast and Analysis
Step 7: Identify Strategic Opportunities
Step 8: Final Review and Market Release
Step 9: Customer Feedback and Market Monitoring
PRODUCT ASSESSMENT
2.1 INTRODUCTION
2.2 PRODUCT PORTFOLIOS
2.2.1 Bone Graft Substitutes
2.2.2 Growth Factors
2.2.2.1 Other Products
2.2.3 Hyaluronic Acid Viscosupplementation (HAV)
2.3 REGULATORY ISSUES AND RECALLS
2.3.1 Bone Graft Substitutes
2.3.1.1 Allografts
2.3.1.1.1 MTF
2.3.1.2 DBM
2.3.1.2.1 AlloSource
2.3.1.2.2 SeaSpine
2.3.1.2.3 RTI Surgical
2.3.1.3 Synthetics
2.3.1.3.1 Abyrx
2.3.1.3.2 Zimmer Biomet
2.3.2 Growth Factors
2.3.2.1.1 Medtronic
2.3.3 Hyaluronic Acid Viscosupplementation
2.3.3.1 Three-injection
2.3.3.1.1 Ferring Pharmaceuticals
2.4 CLINICAL TRIALS
2.4.1 Bone Graft Substitutes
2.4.1.1 Allografts
2.4.1.1.1 Providence Medical Technology
2.4.1.1.2 The University of Texas Health Science
2.4.1.1.3 University of Winchester
2.4.1.2 BDM
2.4.1.2.1 K2M
2.4.1.2.2 Zimmer Biomet
2.4.1.3 Synthetics
2.4.1.3.1 Baxter
2.4.1.3.2 Bonesupport
2.4.1.3.3 DePuy Synthes
2.4.1.3.4 NuVasive
2.4.1.3.5 RTI surgical
2.4.1.3.6 Sunstar GUIDOR
2.4.1.4 Other materials and comparison
2.4.1.4.1 Seoul National University Hospital.
2.4.1.4.2 Sewon Cellontech
2.4.1.4.3 SurgaColl Technologies Limited
2.4.1.4.4 University of Colorado
2.4.1.4.5 University of Padova
2.4.2 Growth Factors
2.4.2.1.1 Bioventus
2.4.2.1.2 Cerapedics
2.4.2.1.3 CGBio
2.4.2.1.4 Isto
2.4.2.1.5 Medtronic
2.4.2.1.6 NuVasive
2.4.2.1.7 Wright
2.4.2.1.8 Others
2.4.3 Hyaluronic Acid Viscosupplementation
2.4.3.1.1 Anika Therapeutics
2.4.3.1.2 Bioventus
2.4.3.1.3 Cairo University
2.4.3.1.4 Ferring Pharmaceuticals
2.4.3.1.5 Federal University of Minas Gerais
2.4.3.1.6 Fidia Pharma USA Inc.
2.4.3.1.7 Istituto Ortopedico Rizzoli
2.4.3.1.8 University Hospital
2.4.3.1.9 Universidade Nova de Lisboa
JAPAN ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW
3.1 INTRODUCTION
3.1.1 Bone Graft Substitutes
3.1.2 Growth Factors
3.1.3 Hyaluronic Acid (HA) Viscosupplementation
3.2 CURRENCY EXCHANGE RATE
3.3 MARKET OVERVIEW AND TREND ANALYSIS
3.4 DRIVERS AND LIMITERS
3.4.1 Market Drivers
3.4.2 Market Limiters
3.5 COMPETITIVE MARKET SHARE ANALYSIS
3.6 MERGERS AND ACQUISITIONS
3.7 COMPANY PROFILES
3.7.1 Anika Therapeutics
3.7.2 Bioventus
3.7.3 DePuy Synthes
3.7.4 Ferring Pharmaceuticals
3.7.5 Fidia Pharmaceuticals
3.7.6 Genzyme (Sanofi Group)
3.7.7 Harvest Technologies (Terumo BCT)
3.7.8 Integra LifeSciences
3.7.9 Medtronic
3.7.10 Musculoskeletal Transplant Foundation (MTF)
3.7.11 NuVasive
3.7.12 Orthofix
3.7.13 RTI Surgical
3.7.14 Stryker
3.7.15 Vericel Corporation (formerly Aastrom Bioscience)
3.7.16 Zimmer Biomet
3.8 SWOT ANALYSIS
3.8.1 Anika Therapeutics
3.8.2 Bioventus
3.8.3 DePuy Synthes
3.8.4 Ferring Pharmaceuticals
3.8.5 Fidia Pharmaceuticals
3.8.7 Harvest Technologies (Terumo BCT)
3.8.8 Integra LifeSciences
3.8.9 Medtronic
3.8.10 Musculoskeletal Transplant Foundation (MTF)
3.8.11 NuVasive
3.8.12 Orthofix
3.8.14 Stryker
3.8.15 Vericel Corporation (formerly Aastrom Bioscience)
3.8.16 Zimmer Biomet
PROCEDURE NUMBERS
4.1 INTRODUCTION
4.2 PROCEDURES
4.2.1 Orthopedic Biomaterial Procedures by Segment
4.2.2 Orthopedic Bone Grafting Procedures
4.2.2.1 Units per Procedure by Indication
4.2.2.2 Autograft Orthopedic Bone Grafting Procedures by Indication
4.2.2.3 Synthetic Orthopedic Bone Grafting Procedures by Indication
4.2.3 Hyaluronic Acid Supplementation Procedures
4.2.3.1 Hyaluronic Acid Supplementation Procedures by Injection Cycle
ORTHOPEDIC BONE GRAFT SUBSTITUTE MARKET
5.1 INTRODUCTION
5.2 MARKET ANALYSIS AND FORECAST
5.2.1.1 Synthetic Bone Graft Substitute Market
5.2.1.1.1 Synthetic Bone Graft Substitute Market by Indication
5.2.1.2 Demineralized Bone Matrix Allograft Bone Graft Substitute Market
5.3 DRIVERS AND LIMITERS
5.3.1 Market Drivers
5.3.2 Market Limiters
5.4 COMPETITIVE MARKET SHARE ANALYSIS
HYALURONIC ACID VISCOSUPPLEMENTATION MARKET
6.1 INTRODUCTION
6.1.1 Benefits of Viscosupplementation
6.1.2 Synovial Fluid
6.2 MARKET OVERVIEW
6.3 MARKET ANALYSIS AND FORECAST
6.3.1 Total Hyaluronic Acid Viscosupplementation Market
6.3.2 Three-Injection Hyaluronic Acid Viscosupplementation Market
6.3.3 Five-Injection Hyaluronic Acid Viscosupplementation Market
6.4 DRIVERS AND LIMITERS
6.4.1 Market Drivers
6.4.2 Market Limiters
6.5 COMPETITIVE MARKET SHARE ANALYSIS
ABBREVIATIONS
List of Charts
Chart 1 1: Orthopedic Biomaterials Market by Segment, Japan, 2016 – 2026
Chart 1 2: Orthopedic Biomaterials Market Overview, Japan, 2019 & 2026
Chart 3 1: Orthopedic Biomaterials Market by Segment, Japan, 2016 – 2026
Chart 3 2: Orthopedic Biomaterials Market Breakdown, Japan, 2019
Chart 3 3: Orthopedic Biomaterials Market Breakdown, Japan, 2026
Chart 3 4: Growth Rates by Segment, Orthopedic Biomaterials Market, Japan, 2017 – 2026
Chart 3 5: Leading Competitors, Orthopedic Biomaterials Market, Japan, 2019
Chart 4 1: Orthopedic Biomaterials Procedures by Segment, Japan, 2016 – 2026
Chart 4 2: Orthopedic Bone Grafting Procedures by Material, Japan, 2016 – 2026
Chart 4 3: Autograft Orthopedic Procedures by Indication, Japan, 2016 – 2026
Chart 4 4: Synthetic Orthopedic Bone Grafting Procedures by Indication, Japan, 2016 – 2026
Chart 4 5: Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle, Japan, 2016 – 2026
Chart 5 1: Synthetic Bone Graft Substitute Market, Japan, 2016 – 2026
Chart 5 2: Synthetic Bone Graft Substitute Market by Indication, Japan, 2016 – 2026
Chart 5 3: Spine Synthetic Market, Japan, 2016 – 2026
Chart 5 4: Cervical Spine Synthetic Market, Japan, 2016 – 2026
Chart 5 5: Thoracolumbar Spine Synthetic Market, Japan, 2016 – 2026
Chart 5 6: Trauma Synthetic Market, Japan, 2016 – 2026
Chart 5 7: Non-Union Trauma Synthetic Market, Japan, 2016 – 2026
Chart 5 8: Fresh Fracture Trauma Synthetic Market, Japan, 2016 – 2026
Chart 5 9: Large Joint Reconstruction Synthetic Market, Japan, 2016 – 2026
Chart 5 10: Hip Reconstruction Synthetic Market, Japan, 2016 – 2026
Chart 5 11: Knee Reconstruction Synthetic Market, Japan, 2016 – 2026
Chart 5 12: Foot Reconstruction Synthetic Market, Japan, 2016 – 2026
Chart 5 13: Craniomaxillofacial Synthetic Market, Japan, 2016 – 2026
Chart 5 14: Oncology Synthetic Market, Japan, 2016 – 2026
Chart 5 15: Leading Competitors, Orthopedic Bone Graft Substitute Market, Japan, 2019
Chart 6 1: Hyaluronic Acid Viscosupplementation Market by Segment, Japan, 2016 – 2026
Chart 6 2: Hyaluronic Acid Viscosupplementation Market Breakdown, Japan, 2019
Chart 6 3: Hyaluronic Acid Viscosupplementation Market Breakdown, Japan, 2026
Chart 6 4: Total Hyaluronic Acid Viscosupplementation Market, Japan, 2016 – 2026
Chart 6 5: Three-Injection Hyaluronic Acid Viscosupplementation Market, Japan, 2016 – 2026
Chart 6 6: Five-Injection Hyaluronic Acid Viscosupplementation Market, Japan, 2016 – 2026
Chart 6 7: Leading Competitors, Hyaluronic Acid Viscosupplementation Market, Japan,
LiST OF Figures
Figure 1 1: Orthopedic Biomaterials Market Share Ranking by Segment, Japan, 2019
Figure 1 2: Companies Researched in this Report
Figure 1 3: Factors Impacting the Orthopedic Biomaterials Market by Segment, Japan
Figure 1 4: Recent Events in the Orthopedic Biomaterials Market, Japan, 2017 – 2019
Figure 1 5: Orthopedic Biomaterials Procedures Covered, Japan
Figure 1 6: Orthopedic Biomaterials Markets Covered, Japan
Figure 1 7: Version History
Figure 2 1: Bone Graft Substitutes Products by Company (1 of 4)
Figure 2 2: Bone Graft Substitutes Products by Company (2 of 4)
Figure 2 3: Bone Graft Substitutes Products by Company (3 of 4)
Figure 2 4: Bone Graft Substitutes Products by Company (4 of 4)
Figure 2 5: Growth Factor Products by Company
Figure 2 6: Hyaluronic Acid Viscosupplementation by Products by Company
Figure 2 7: Class 2 Device Recall Musculoskeletal Transplant Foundation Allofix Insertion Kit
Figure 2 8: Class 2 Device Recall AlloFuse DBM Putty 5cc
Figure 2 9: Class 2 Device Recall Accell Evo3c Demineralized Bone Matrix Putty
Figure 2 10: Class 2 Device Recall RTI Biologics BioSet IC RT Paste 2 cc
Figure 2 11: Class 2 Device Recall Hemostatic Bone Putty
Figure 2 12: Class 2 Device Recall Endobon Xenograft Granules
Figure 2 13: Class 2 Device Recall Endobon Xenograft Granules
Figure 2 14: Class 2 Device Recall INFUSE Bone Graft X SMALL KIT
Figure 2 15: Class 3 Device Recall Euflexxa (1 sodium hyaluronate)
Figure 2 16: Evaluation of DTRAX Graft in Patients with Cervical Degenerative Disc Disease
Figure 2 17: Ridge Preservation Using FDBA and a Collagen Wound Dressing in Molar Sites.
Figure 2 18: Assessing Physical Activity Levels of Patients Following HTO.
Figure 2 19: Evaluation of Fusion Rate Using K2M VESUVIUS® Demineralized Fibers with K2M EVEREST® Spinal System
Figure 2 20: Evaluation of Zimmer Puros® Allograft vs. Creos™ Allograft for Alveolar Ridge Preservation
Figure 2 21: Synthetic Bone Graft Substitute vs. Autologous Spongiosa in Revision Anterior Cruciate Ligament Reconstruction
Figure 2 22: Cerament Treatment of Fracture Defects (CERTiFy)
Figure 2 23: Comparison of Bioactive Glass and Beta-Tricalcium Phosphate as Bone Graft Substitute (BAGvsTCP)
Figure 2 24: Evaluation of Fusion Rate of Anterior Cervical Discectomy and Fusion (ACDF) Using Cervios ChronOs™ and Bonion™
Figure 2 25: AttraX® Putty vs. Autograft in XLIF®
Figure 2 26: Comparison of nanOss Bioactive with Autograft and Bone Marrow Aspirate to Autograft in the Posterolateral Spine
Figure 2 27: Assessment of nanOss Bioactive 3D in the Posterolateral Spine
Figure 2 28: Assessment of Ridge Preservation Using Moldable Beta-tricalcium Phosphate Bone Grafting System
Figure 2 29: Outcome Comparison of Allograft and Synthetic Bone Substitute in High Tibial Osteotomy
Figure 2 30: Efficacy and Safety of SurgiFill™ on Spinal Fusion
Figure 2 31: Assessment of HydroxyColl Bone Graft Substitute in High Tibial Osteotomy Wedge Grafting. (HColl_HTO)
Figure 2 32: Outcomes of the Evans Calcaneal Lengthening Based on Bone Grafting Material
Figure 2 33: Deproteinized Bovine Bone in Alveolar Bone Critical Size Defect (>2cm) Secondary to Cyst Removal
Figure 2 34: A Prospective Study of Instrumented, Posterolateral Lumbar Fusions (PLF) With OsteoAMP®
Figure 2 35: The Clinical Effect of i-FACTOR® Versus Allograft in Non-instrumented Posterolateral Spondylodesis Operation
Figure 2 36: Clinical Study of Injectable Ceramics Bone Graft Substitute Containing rhBMP-2
Figure 2 37: Prospective Study of Safety and Efficacy of InQu® Bone Graft Extender in Lumbar Interbody Fusion Surgery (Intebody)
Figure 2 38: A Study of INFUSE Bone Graft (BMP-2) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis Type 1
Figure 2 39: Clinical Study of INFUSE® Bone Graft Compared to Autogenous Bone Graft for Vertical Ridge Augmentation
Figure 2 40: Parallel Study Between BMP-2 and Autologous Bone Graft After Ilizarow Treatment
Figure 2 41: RCT of AttraX® Putty vs. Autograft in Instrumented Posterolateral Spinal Fusion (AxA)
Figure 2 42: Long-term Safety and Effectiveness of AUGMENT® Bone Graft Compared to Autologous Bone Graft
Figure 2 43: rhBMP-2 vs Autologous Bone Grafting for the Treatment of Non-union of the Docking Site in Tibial Bone Transport
Figure 2 44: Evaluation of Radiculitis Following Use of Bone Morphogenetic Protein-2 for Interbody Arthrodesis in Spinal Surgery
Figure 2 45: Study of Cingal™ for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide at 39 Weeks Follow-Up (Cingal17-02)
Figure 2 46: HyaloFAST Trial for Repair of Articular Cartilage in the Knee (FastTRACK)
Figure 2 47: Effectiveness of Two Hyaluronic Acids in Osteoarthritis of the Knee
Figure 2 48: The Effect of Topical Application of Hyaluronic Acid on Immediate Dental Implant
Figure 2 49: To Look at the Characteristics of Synovial Fluid and Cartilage Matrix in Osteoarthritic Knees After Hyaluronic Acid Injection
Figure 2 50: Use of Hyaluronic Acid as a Therapeutic Strategy for Bone Repair in Humans
Figure 2 51: Two Weekly Intra-articular Hyaluronan Knee Injections, Given One Week Apart, of HYMOVIS Combined With a Physical Exercise Program (PEP) Compared to PEP Alone, in a Relatively Young, Active Population of Subjects With Patellofemoral Osteoarthritis (PFOA) and/or Tibiofemoral Osteoarthritis (TFOA)
Figure 2 52: Comparative Assessment of Viscosupplementation With Polynucleotides and Hyaluronic Acid (PNHA1401)
Figure 2 53: Trial Comparing Botulin Toxin Versus Hyaluronic Acid by Intra-articular Injection (GOTOX)
Figure 2 54: Trial to Assess the Structural Effect and Long-term Symptomatic Relief of Intra-articular Injections of HA (ViscOA)
Figure 3 1: Currency Exchange Rate, 2019
Figure 3 2: Orthopedic Biomaterials Market by Segment, Japan, 2016 – 2026 (US$M)
Figure 3 3: Orthopedic Biomaterials Market by Segment, Japan, 2016 – 2026 (JP¥M)
Figure 3 4: Orthopedic Biomaterials Market Growth by Segment, Japan, 2016 – 2026
Figure 3 5: Drivers and Limiters, Orthopedic Biomaterials Market, Japan, 2019
Figure 3 6: Leading Competitors, Orthopedic Biomaterials Market, Japan, 2019
Figure 3 7: SWOT Analysis, Anika Therapeutics (1 of 2)
Figure 3 8: SWOT Analysis, Anika Therapeutics (2 of 2)
Figure 3 9: SWOT Analysis, Bioventus (1 of 2)
Figure 3 10: SWOT Analysis, Bioventus (2 of 2)
Figure 3 11: SWOT Analysis, DePuy Synthes
Figure 3 12: SWOT Analysis, Ferring Pharmaceuticals
Figure 3 13: SWOT Analysis, Fidia Pharmaceuticals
Figure 3 14: SWOT Analysis, Genzyme (Sanofi)
Figure 3 15: SWOT Analysis, Harvest Technologies
Figure 3 16: SWOT Analysis, Integra LifeSciences
Figure 3 17: SWOT Analysis, Medtronic
Figure 3 18: SWOT Analysis, MTF
Figure 3 19: SWOT Analysis, NuVasive
Figure 3 20: SWOT Analysis, Orthofix
Figure 3 21: SWOT Analysis, RTI Surgical
Figure 3 22: SWOT Analysis, Stryker
Figure 3 23: SWOT Analysis, Vericel Corporation
Figure 3 24: SWOT Analysis, Zimmer Biomet (1 of 2)
Figure 3 25: SWOT Analysis, Zimmer Biomet (2 of 2)
Figure 4 1: Orthopedic Biomaterials Procedures by Segment, Japan, 2016 – 2026
Figure 4 2: Orthopedic Bone Grafting Procedures by Material, Japan, 2016 – 2026
Figure 4 3: Units per Procedure by Indication, Bone Graft Substitute Market, Japan, 2016– 2026
Figure 4 4: Autograft Orthopedic Procedures by Indication, Japan, 2016 – 2026 (1 of 2)
Figure 4 5: Autograft Orthopedic Procedures by Indication, Japan, 2016 – 2026 (2 of 2)
Figure 4 6: Synthetic Orthopedic Bone Grafting Procedures by Indication, Japan, 2016 – 2026 (1 of 2)
Figure 4 7: Synthetic Orthopedic Bone Grafting Procedures, Japan, 2016 – 2026 (2 of 2)
Figure 4 8: Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle, Japan, 2016 – 2026
Figure 5 1: Synthetic Bone Graft Substitute Market, Japan, 2016 – 2026
Figure 5 2: Synthetic Bone Graft Substitute Market by Indication, Japan, 2016 – 2026 (US$M)
Figure 5 3: Spine Synthetic Market, Japan, 2016 – 2026
Figure 5 4: Cervical Spine Synthetic Market, Japan, 2016 – 2026
Figure 5 5: Thoracolumbar Spine Synthetic Market, Japan, 2016 – 2026
Figure 5 6: Trauma Synthetic Market, Japan, 2016 – 2026
Figure 5 7: Non-Union Trauma Synthetic Market, Japan, 2016 – 2026
Figure 5 8: Fresh Fracture Trauma Synthetic Market, Japan, 2016 – 2026
Figure 5 9: Large Joint Reconstruction Synthetic Market, Japan, 2016 – 2026
Figure 5 10: Hip Reconstruction Synthetic Market, Japan, 2016 – 2026
Figure 5 11: Knee Reconstruction Synthetic Market, Japan, 2016 – 2026
Figure 5 12: Foot Reconstruction Synthetic Market, Japan, 2016 – 2026
Figure 5 13: Craniomaxillofacial Synthetic Market, Japan, 2016 – 2026
Figure 5 14: Oncology Synthetic Market, Japan, 2016 – 2026
Figure 5 15: Drivers and Limiters, Orthopedic Bone Graft Substitute Market, Japan, 2019
Figure 5 16: Leading Competitors, Orthopedic Bone Graft Substitute Market, Japan, 2019
Figure 6 1: Hyaluronic Acid Viscosupplementation Market by Segment, Japan, 2016 – 2026 (US$M)
Figure 6 2: Hyaluronic Acid Viscosupplementation Market by Segment, Japan, 2016 – 2026 (JP¥M)
Figure 6 3: Total Hyaluronic Acid Viscosupplementation Market, Japan, 2016 – 2026
Figure 6 4: Three-Injection Hyaluronic Acid Viscosupplementation Market, Japan, 2016 – 2026
Figure 6 5: Five-Injection Hyaluronic Acid Viscosupplementation Market, Japan, 2016 – 2026
Figure 6 6: Drivers and Limiters, Hyaluronic Acid Viscosupplementation Market, Japan, 2019
Figure 6 7: Leading Competitors, Hyaluronic Acid Viscosupplementation Market, Japan, 2019

$7,995
$8,995
$9,995

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks